ROME--(Marketwire - September 08, 2008) - Novo Nordisk (NYSE: NVO), a global healthcare company, presented data from a phase 3 clinical study (LEAD™ 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering (HBA1c), weight loss, blood pressure reduction and improvements in beta-cell functioning.
